CDMO BUSINESS
Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%
Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target price by 23% to Rs 12,550, citing robust CDMO business expansion, strong EBITDA margins, and a solid GLP peptide pipeline.
Divi's Labs shares jump 8% to fresh 52-week high after Q2 profit soars 64% YoY. What brokerages say after bumper results?
Divi’s Laboratories shares surged over 8% during Muhurat Trading, hitting a 52-week high after Q2 FY27 net profit jumped 64% to ₹1,127 crore. Revenue grew 35%, while brokerages differed on valuation concerns and future growth prospects.
PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horses
HDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 2083. He favours largecaps for valuation comfort, highlights selective stock opportunities and urges investors to prioritise earnings visibility and disciplined asset allocation.
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles
India's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers businesses towards complex generics, peptides, biologics, contract manufacturing and advanced therapeutics. Laurus Labs, Granules India, Bharat Biotech, Sun Pharma and Torrent Pharma are investing in capabilities that require greater scientific expertise, significant capital and longer gestation periods. The key question is whether the successors can turn these long-term bets into sustainable growth and create lasting value for investors.
Pharma industry steps up API investments to cut import dependence, move up value chain
India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.
Alivus Life Sciences block deal: Promoter Nirma sells over 28 lakh shares worth Rs 390 crore; Norges Bank, Helios MF among buyers
Nirma sold 28.46 lakh Alivus Life Sciences shares worth Rs 390 crore through a block deal at Rs 1,370 apiece. Norges Bank, Bandhan MF and others bought shares as Alivus reported strong Q2FY27 earnings growth.
- Go To Page 1
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
Global markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at the end of last week were at about $118 to the barrel, are now under $95. The hope clearly is that Democrat control of both chambers of the US Congress will pressure the Trump administration to pursue a diplomatic end to the conflict with Iran in the Gulf.
Beyond tech: Kotak MF’s Shibani Kurian on India’s next innovation-led winners
Innovation-led investment opportunities in India are extending well beyond technology, with healthcare, auto components and industrials emerging as key areas of interest, according to Shibani Kurian, Head of Equity Research and Senior Fund Manager at Kotak Mahindra AMC. “Innovation can be seen across sectors and not necessarily limited to technology,” she said.
Diwali investment picks 2026: 10 fund managers reveal promising opportunities and risks to watch
This Diwali, investment experts advise a strategic approach focused on asset allocation rather than luring high-growth stocks. Sectors like banking, financial services, and premium goods present promising opportunities. While gold should only occupy a small fraction of a diversified portfolio for risk management, short-duration debt funds gain favour as interest rates shift. Maintaining discipline and patience is essential for long-term investment success.
How Indian investors’ portfolios are changing: From property and gold to SIPs and ETFs
Indian households are re-evaluating their asset allocations as gold holdings rise and equity investments remain stable. Recent data reveals a significant increase in household wealth, particularly in gold and real estate. Households are moving from traditional savings to market investments, notably through systematic investment plans. Meanwhile, financial behaviors are changing, with more monthly contributions being made to equities.
Diwali 2026: 77 stocks knock down D-St bears to deliver multibagger returns of up to 4,700% in a year
With Diwali 2026 on the horizon, 77 stocks have thrived despite market fluctuations, marking exceptional returns. Mrugesh Trading showcases an astonishing gain of 4,657%, while Axis Solution follows closely with 1,081%. Other strong performers are Sterlite Technologies and Cupid, each demonstrating impressive growth. Analysts are hopeful for a market rebound thanks to falling crude oil prices, which could positively impact sectors such as automotive, capital goods, and pharmaceuticals.
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-year to Rs 2,206 crore, while net profit more than doubled to Rs 441 crore. Growth was supported by sustained momentum in its CDMO business and Affordable Medicines division, alongside improving margins and continued investments in manufacturing capabilities.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
When a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling used cars reported numbers that fell short, and the street punished the stock severely. But it is not just the clear misses. Anything that is well-owned and presents disappointing numbers is seeing double-digit cuts.
Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal
In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.
Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally
Dr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America weakness pressured performance, offset partly by growth in India and emerging markets, alongside biosimilar approvals and strategic partnerships.
From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plans
Biodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture will notably elevate its production capacities and diversify its contract development and manufacturing services. Biodeal is committed to fortifying existing partnerships with clients leveraging its innovative nasal and oral drug formulations.
From CDMO to aerospace: How Vikas Khemani finds India’s next big themes
Now, as Carnelian has ventured into mutual fund business by launching a small-cap fund with a ₹5,000 crore cap, Khemani is focusing on manufacturing, financials and IT while warning investors against confusing market capitalisation with valuation. In an interview, he explains how the fund plans to manage size, assess expensive growth opportunities and position for the next market re-rating.
ETMarkets Smart Talk | Manufacturing, healthcare and financialisation could create India’s next wealth creators: Sanjay Doshi
Abakkus Mutual Fund’s Sanjay Doshi sees opportunities across market capitalisations, despite elevated mid- and smallcap valuations. He urges investors to prioritise sustainable earnings, cash flows and returns on capital, maintain disciplined stock selection and align SIP allocations with long-term goals.
Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside
Nuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upside from the current market price. The brokerage expects the drugmaker’s shift from its traditional anti-retroviral (ARV) business towards contract development and manufacturing (CDMO) to drive its next phase of growth.
Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watch
India's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabilities. Jefferies emphasizes the critical role of specialized manufacturing skills and a strong project pipeline for achieving success. With Divi's Laboratories and Sai Life Sciences excelling in these domains, there is potential for notable earnings growth.
CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbook
At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated products to expand their global footprint as geopolitical and supply-chain risks reshape the industry.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Anupam Rasayan eyes US, Europe pharma push after Bliss deal, one-third revenue from drugs
Anupam Rasayan India Ltd anticipates significant growth in its pharmaceutical segment over the next three years. The company expects pharmaceuticals to comprise one-third of overall revenue driven by the acquisition of Bliss GVS Pharma. Anupam's ability to offer integrated contract manufacturing services will facilitate its expansion in the US and Europe. Bliss currently operates at low capacity and presents opportunities for increased utilization.
Nifty valuations near post-Covid lows. Alchemy Capital’s Alok Agarwal explains what investors should buy now
Nifty valuations have reset sharply from 2024 levels and are now near post-Covid lows, says Alchemy Capital’s Alok Agarwal. He sees the next phase of market growth broadening beyond large caps. Mid- and small-caps, AI infrastructure, healthcare, manufacturing and select defence companies offer opportunities, while global yields and FPI flows remain key.
Kotak warns small and midcap euphoria may turn sour as investors chase quick returns
India’s stock market shows a sharp divide, with investors favouring small and midcaps despite stretched valuations while overlooking relatively attractive largecaps. Kotak Institutional Equities says price momentum and popular growth narratives are driving sentiment more than underlying value and fundamentals.
Avoid chasing small-cap outperformers; valuations look attractive for long-term investors: Pratik Dharmshi, Union MF
With small-cap valuations turning more reasonable and earnings growth improving, Pratik Dharmshi, Fund Manager – Equity at Union AMC, remains constructive on the segment. He recommends focusing on quality businesses with sustainable earnings potential, avoiding the chase for recent outperformers, and maintaining a 5-7 year investment horizon while staying mindful of liquidity and volatility risks.
Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacity
Aragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-molecule CDMO capacity and a biologics facility. Aragen aims to transition from a molecules company to a medicines company through expansion. This strategic move aligns with global drugmakers seeking supply chain alternatives outside China. The firm is also developing its own intellectual property around antibody-drug conjugates.
3 smallcap mutual funds returned over 23% in 2026. These 5 stocks feature in all their portfolios
In 2026, three smallcap mutual funds delivered remarkable returns exceeding twenty-three percent. Notably, these outstanding funds uniformly included five key stock picks. Acutaas Chemicals and Anand Rathi Wealth stood out as popular choices, complemented by other names like Sky Gold and Diamonds, Syrma SGS Technology, and TD Power Systems. Such investments underscore a strong belief in industrial advancement and the robustness of domestic capital markets.
Load More
